Shinichi Kobayashi

Showa University — Japan

Pharmacology, Toxicology and Pharmaceutics · Life Sciences

40h-index6.1kcitations514works2.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pharmacogenetics and Drug Metabolism(28), Drug Transport and Resistance Mechanisms(23), Viral gastroenteritis research and epidemiology(21), Cancer Immunotherapy and Biomarkers(20), Cardiac electrophysiology and arrhythmias(18)

Publications514 total

The Limited Impact of Pre-existing Rheumatologic Diseases on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Propensity–Score Matched Analysis
Transplantation and Cellular Therapy·2025
Platelet Recovery and Its Impact on Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation: A Japanese Nationwide Retrospective Study
American Journal of Hematology·2025Open Access
Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot Study
Cancers·2025Open Access
Efficacy of Tucidinostat Pre-emptive Therapy for Peripheral T-cell Lymphoma after Allogeneic Stem Cell Transplantation
Internal Medicine·2025· 1 citedOpen Access
Combination therapy with levofloxacin and the probiotic <i>Clostridium butyricum</i><scp>MIYAIRI</scp> 588 enhances immune checkpoint inhibitor efficacy
International Journal of Cancer·2025· 4 cited
Veillonella and Streptococcus are associated with aging of the gut microbiota and affect the efficacy of immune checkpoint inhibitors
Frontiers in Immunology·2025· 3 citedOpen Access
Abstract CT032: Promotive clinical effects of pembrolizumab with necitumumab in patients having advanced non-small cell lung cancer with PD-L1 expression of 50% or higher in a phase II study (K-TAIL-202)
Cancer Research·2024· 1 cited
Butyricimonas is a key gut microbiome component for predicting postoperative recurrence of esophageal cancer
Cancer Immunology Immunotherapy·2024· 9 citedOpen Access
Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefit
Cancer Science·2024· 6 citedOpen Access
Non-classical Monocytes Enhance the Efficacy of Immune Checkpoint Inhibitors on Colon Cancer in a Syngeneic Mouse Model
Anticancer Research·2023· 2 citedOpen Access
Corrigendum: Soluble PD−L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis
Frontiers in Immunology·2023· 2 citedOpen Access
Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis
Frontiers in Immunology·2023· 12 citedOpen Access
OC 69.4 Safety, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous Injection of NXT007, an Emicizumab-Based Next-Generation Bispecific Antibody, in Healthy Volunteers (NXTAGE Study)
Research and Practice in Thrombosis and Haemostasis·2023· 1 citedOpen Access
Butyricimonas is a key gut microbiome component for predicting postoperative recurrence of esophageal cancer
Research Square (Research Square)·2023· 1 citedOpen Access
Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors
Frontiers in Immunology·2023· 2 citedOpen Access
Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy
Oncology Letters·2023· 13 citedOpen Access
Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor
Frontiers in Immunology·2023· 36 citedOpen Access
Figure S6 from Identification of Membrane-expressed CAPRIN-1 as a Novel and Universal Cancer Target, and Generation of a Therapeutic Anti-CAPRIN-1 Antibody TRK-950
2023Open Access
Identification of Membrane-expressed CAPRIN-1 as a Novel and Universal Cancer Target, and Generation of a Therapeutic Anti-CAPRIN-1 Antibody TRK-950
Cancer Research Communications·2023· 16 citedOpen Access
Figure S6 from Identification of Membrane-expressed CAPRIN-1 as a Novel and Universal Cancer Target, and Generation of a Therapeutic Anti-CAPRIN-1 Antibody TRK-950
2023Open Access
page 1 of 26Next →

Frequent Co-authors

Toshio Kumai(14), Naoki Matsumoto(7), Kenji Sakae(6), Minoru Watanabe(5), Takehiko Sambe(4), KOUICHI TSUCHIYA(4), Yasushi Kitaoka(4), Yasunari Munemasa(4), Satoki Ueno(4), Yuichi Ishihara(3), Shin Isomura(3), Naoki Uchida(3), Katsuro Natori(3), Naokazu Takeda(3), Taizo Nakagawa(3), K. Kuribayashi(3), Kazuyuki Isenoumi(3), Teruo Yamashita(3), Hiroko Minagawa(3), Masami Tanaka(3)